Synergistic effects of mycophenolate mofetil and sirolimus in prevention of acute heart, pancreas, and kidney allograft rejection and in reversal of ongoing heart allograft rejection in the rat.

BACKGROUND The effect of mycophenolate mofetil (MMF) and sirolimus (rapamycin, RAPA) mono- and combination-therapy was examined in prevention of acute heart, pancreas, and kidney allograft rejection and in reversal of ongoing heart allograft rejection in the rat. METHODS Both drugs were administered orally for up to 30 days. Eleven groups (n=6) were involved in the first part of the heart allografting model. Brown Norway (RT1n) to Lewis (RT1(1)) combination was used in the heart and pancreas transplantation models, whereas Buffalo (RT1b) to Wistar Furth (RT1u) was used in the kidney transplantation model. RESULTS The naive control group showed a mean survival time of 6.5+/-0.6 days. There were graded dose-responses to monotherapy of MMF 10 and 20 mg(kg/ day (12.5+/-2.6 days; 19.3+/-9.0 days) and RAPA 0.2, 0.4, 0.8, and 1.8 mg/kg/day (19.2+/-2.0 days; 30.0+/-7.3 days; 50.8+/-12.5 days; 51.2+/-2.6 days), respectively (P=0.001). Results with the combined use of drugs indicate that a synergistic or very strong synergistic interaction was produced when compared with monotherapy of MMF or RAPA: MMF 10 mg(kg/day+RAPA 0.2 mg/kg(day (52.7+/-5.7 days, combination index [CI] =0.189), MMF 20 mg(kg/day+RAPA 0.2 mg/kg/day (57.7+/-5.7 days, CI=0.084), MMF 10 mg/kg/day+RAPA 0.4 mg(kg/day (50.2+/-13.5 days, CI=0.453), and MMF 20 mg/kg(day+ RAPA 0.4 mg/kg(day (51.5+/-6.8 days, CI=0.439), respectively. These results were repeatable in the prevention of acute pancreas and kidney allograft rejection in the rat. In the second part of the study of reversal of ongoing acute heart allograft rejection model, the combined treatment of MMF 10 mg/kg(day+RAPA 0.2 mg/ kg(day (35.5+/-16.0 days, CI=0.794) and MMF 20 mg/kg day+RAPA 0.2 mg(kg/day (57.2+/-4.7 days, CI=0.310) represented synergistic interaction compared with monotherapy of MMF or RAPA. CONCLUSIONS Concomitant therapy of MMF and RAPA produces a synergistic effect in prevention of heart, pancreas, and kidney allograft rejection and in reversal of ongoing heart allograft rejection in the rat.

[1]  S. Busque,et al.  Tacrolimus (FK506) and sirolimus (rapamycin) in combination are not antagonistic but produce extended graft survival in cardiac transplantation in the rat. , 1997, Transplantation.

[2]  S. Gruber,et al.  Sirolimus, a New, Potent Immunosuppressive Agent , 1997, Pharmacotherapy.

[3]  B D Kahan,et al.  Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats. , 1996, Transplantation.

[4]  H. Sollinger,et al.  Mycophenolate mofetil--clinical and experimental experience. , 1996, Therapeutic drug monitoring.

[5]  G. Remuzzi,et al.  A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. , 1996, Transplantation.

[6]  A. Monaco,et al.  Effect of rapamycin on renal allograft survival in canine recipients treated with antilymphocyte serum, donor bone marrow, and cyclosporine. , 1995, Transplantation.

[7]  J. Wu,et al.  Rapamycin-induced long-term allograft survival depends on persistence of alloantigen. , 1994, Journal of immunology.

[8]  M. Deierhoi,et al.  The incidence of subsequent acute rejection following the treatment of refractory renal allograft rejection with mycophenolate mofetil (RS61443). , 1994, Transplantation.

[9]  T. Ocain,et al.  Rapamycin: A novel immunosuppressive macrolide , 1994, Medicinal research reviews.

[10]  B. Leaker,et al.  Clinical aspects of cyclosporin nephrotoxicity. , 1994, British journal of hospital medicine.

[11]  W. Davis,et al.  PIG AORTIC ENDOTHELIAL CELL ANTIGENS RECOGNIZED BY HUMAN IgM NATURAL ANTIBODIES , 1993, Transplantation.

[12]  Hongyu Luo,et al.  REVERSAL OF ONGOING HEART, KIDNEY, AND PANCREAS ALLOGRAFT REJECTION AND SUPPRESSION OF ACCELERATED HEART ALLOGRAFT REJECTION IN THE RAT BY RAPAMYCIN , 1993, Transplantation.

[13]  K. Shirabe,et al.  RAPAMYCIN: IMMUNOSUPPRESSION, HYPORESPONSIVENESS, AND SIDE EFFECTS IN A PORCINE RENAL ALLOGRAFT MODEL , 1993, Transplantation.

[14]  J. Wu,et al.  Long-term in vivo effects of rapamycin on humoral and cellular immune responses in the rat. , 1993, Immunobiology.

[15]  K. Isono,et al.  EFFECTS OF RAPAMYCIN IN EXPERIMENTAL ORGAN ALLOGRAFTING , 1993, Transplantation.

[16]  W. Bechstein,et al.  RS-61443/cyclosporine combination therapy prolongs canine liver allograft survival. , 1993, Transplantation proceedings.

[17]  B. Kahan,et al.  Low-dose rapamycin potentiates the effects of subtherapeutic doses of cyclosporine to prolong renal allograft survival in the mongrel canine model. , 1993, Transplantation.

[18]  G. Klintmalm,et al.  RS‐61443 (Mycophenolate Mofetil) A Multicenter Study for Refractory Kidney Transplant Rejection , 1992, Annals of surgery.

[19]  B. Kahan,et al.  The effect of rapamycin on orthotopic small bowel transplantation in the rat. , 1992, Transplantation proceedings.

[20]  Hongyu Luo,et al.  INHIBITION OF IN VITRO IMMUNOGLOBULIN PRODUCTION BY RAPAMYCIN1 , 1992, Transplantation.

[21]  J. Mason.  The effect of cyclosporin on renal function. , 1992, Journal of autoimmunity.

[22]  R. Morris.  Rapamycins: Antifungal, antitumor, antiproliferative, and immunosuppressive macrolides , 1992 .

[23]  C. Lang,et al.  Cyclosporin-induced nephrotoxicity and hypertension. , 1992, British journal of hospital medicine.

[24]  W. Bechstein,et al.  RS-61443 reverses acute allograft rejection in dogs. , 1991, Surgery.

[25]  P. Friend,et al.  Rapamycin in experimental renal allografts in primates. , 1991, Transplantation proceedings.

[26]  J. Wu,et al.  Rapamycin suppresses in vitro immunoglobulin production by human lymphocytes. , 1991, Transplantation proceedings.

[27]  P. Daloze,et al.  Reversal of ongoing rejection of allografts by rapamycin. , 1991, Transplantation proceedings.

[28]  P. Daloze,et al.  The immunosuppressive effect of rapamycin on pancreaticoduodenal transplants in the rat. , 1991, Transplantation proceedings.

[29]  A. Allison,et al.  Immunosuppressive effects of the morpholinoethyl ester of mycophenolic acid (RS-61443) in rat and nonhuman primate recipients of heart allografts. , 1991, Transplantation proceedings.

[30]  A. Allison,et al.  Lymphocyte‐Selective Cytostatic and Immunosuppressive Effects of Mycophenolic Acid in Vitro: Role of Deoxyguanosine Nucleotide Depletion , 1991, Scandinavian journal of immunology.

[31]  A. Allison,et al.  Lymphocyte‐Selective Antiproliferative and Immunosuppressive Effects of Mycophenolic Acid in Mice , 1991, Scandinavian journal of immunology.

[32]  S. Stepkowski,et al.  Rapamycin, a potent immunosuppressive drug for vascularized heart, kidney, and small bowel transplantation in the rat. , 1991, Transplantation.

[33]  D. Eckhoff,et al.  RS-61443--a new, potent immunosuppressive agent. , 1991, Transplantation.

[34]  A. Allison,et al.  Mycophenolic acid morpholinoethylester (RS-61443) is a new immunosuppressant that prevents and halts heart allograft rejection by selective inhibition of T- and B-cell purine synthesis. , 1990, Transplantation proceedings.

[35]  B D Kahan,et al.  Analysis of the interactions of immunosuppressive drugs with cyclosporine in inhibiting DNA proliferation. , 1990, Transplantation.

[36]  S. Thiru,et al.  RAPAMYCIN FOR IMMUNOSUPPRESSION IN ORGAN ALLOGRAFTING , 1989, The Lancet.

[37]  B. Kahan.  Drug therapy: cyclosporine , 1989 .

[38]  A. Nademanee,et al.  Ganciclovir/immunoglobulin combination therapy for the treatment of human cytomegalovirus-associated interstitial pneumonia in bone marrow allograft recipients. , 1988, Transplantation.

[39]  B. Ryffel,et al.  CYCLOSPORINE—RELATIONSHIP OF SIDE EFFECTS TO MODE OF ACTION , 1988, Transplantation.

[40]  Borel Jf.  Cyclosporins: basic science summary. , 1988 .

[41]  G. Abouna,et al.  Correlation of blood levels and tissue levels of cyclosporine with the histologic features of cyclosporine toxicity. , 1988, Transplantation proceedings.

[42]  D. Brahams.  Human immunodeficiency virus and the law. , 1987, Lancet.

[43]  A. D. de Macedo,et al.  Pancreaticoduodenal transplantation in the rat. A technique update. , 1986, Transplantation.

[44]  T. Strom,et al.  Experience with Cyclosporine and Steroids in Clinical Renal Transplantation , 1984, Annals of surgery.

[45]  B. Kahan.  Cyclosporine: a powerful addition to the immunosuppressive armamentarium. , 1984, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[46]  S. Sehgal,et al.  Rapamycin (AY-22,989), a new antifungal antibiotic. III. In vitro and in vivo evaluation. , 1978, The Journal of antibiotics.

[47]  S. Sehgal,et al.  Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.:II. FERMENTATION, ISOLATION AND CHARACTERIZATION , 1975 .

[48]  S. Sehgal,et al.  Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. , 1975, The Journal of antibiotics.

[49]  R. Schwartz,et al.  Immunosuppressive therapy. 1. , 1972, The New England journal of medicine.

[50]  Hill Mm.  Living organisms in patent law. , 1970 .

[51]  K Ono,et al.  Improved technique of heart transplantation in rats. , 1969, The Journal of thoracic and cardiovascular surgery.

[52]  Lee Sh,et al.  Microvascular surgical techniques in research, with special reference to renal transplantation in the rat , 1965 .